Date: Nov 26, 2013
Job Function: Research
Schedule : Full-time
Job Level: Experienced
Who We Are
At the Roche Group, about 80,000 people across 150 countries are pushing back the frontiers of healthcare. Working together, we've become one of the world's leading research-focused healthcare groups. A member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 30 years, using human genetic information to develop novel medicines for serious and life-threatening diseases. The headquarters for Roche pharmaceutical operations in the United States, Genentech has multiple therapies on the market for cancer and other serious illnesses. Please take this opportunity to learn about Genentech, where we believe that our employees are our most important asset and are dedicated to remaining a great place to work.
A position is available fora postdoctoral fellow with expertise in crystallography to join the
Department of StructuralBiology at Genentech, Inc. Active areas of research include the structure andfunction of extracellular and intracellular signaling cascades and of proteincomplexes relevant to human disease. The successful candidate will be involvedin all aspects of crystallography, including expression and purification ofproteins, crystallization, data collection, structure determination andanalysis of protein structures.
Who You Are
Highly motivated candidatesare sought who are capable of independent work in a collaborative environment.Candidates must have a Ph.D. in structural biology, biophysics, biochemistry orrelated discipline. Candidates should have a strong background in protein crystallographyand structure determination as well as demonstrated by successful purification,characterization and crystallization of challenging proteins as evidenced by afirst author paper published or accepted in a peer-reviewed journal.Familiarity with biophysical techniques is a plus.
Sudhamsu J, Yin, JP, Chiang, E, Starovasnik M, GroganJL, Hymowitz, SG. Dimerization of LTRby LTa2 is necessary and sufficient for signal transduction. Proceedings of the National Academy ofSciences, 2013: published ahead of print November 18,2013, doi: 10.1073/pnas.1310838110
De Leon G, Bowman KK, Feng JA, Crawford T, Everett C, FrankeY, Oh A, Stanley M, Staben ST, Starovasnik MA, Wallweber HJA , Wu J, Wu LC,Johnson A, Hymowitz SG. The crystalstructure of the catalytic domain of the NF-kB Inducing Kinase reveals a narrowbut flexible active site. Structure, 2013, 20:1704-1714.
BosanacI, Wertz IE, Pan B, Yu C, Kusam S, Lam C, Phu L, Phun Q, Maurer B, Arnott D,Kirkpatrick DS, Dixit VM, Hymowitz SG. Ubiquitin binding to A20 ZnF4 isrequired for modulation of NF-kB signaling. Molecular Cell, 2010, 40:548-557.
WuY, Cain-Hom C, Choi L, de Leon GP, Chen Y, Wu X, Ridgway J, Schahin-Reed D, DowGJ, Hagenbeek TJ, Stawicki S, Watts RJ, Zhang J, Choy R, Howard P, Kadyk L, YanM, Callahan CA, Hymowitz SG, Siebel CW. Stabilizing receptor quiescence withsynthetic antibodies enables therapeutic targeting of individual Notchreceptors. Nature, 2010, 464:1052-1057.
Genentech is an Equal Opportunity Employer.
Apply Here: http://www.Click2apply.net/yy9wk7q